-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulviprubart in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulviprubart in Inclusion Body Myositis (IBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulviprubart in Inclusion Body Myositis (IBM) Drug Details: Ulviprubart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide in Inclusion Body Myositis (IBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Inclusion Body Myositis (IBM) Drug Details: Froniglutide...
-
Product Insights
NewInclusion Body Myositis (IBM) – Drugs In Development, 2024
Empower your strategies with our Inclusion Body Myositis (IBM) – Drugs In Development, 2024 report and make more profitable business decisions. Inclusion body myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot. The...
-
Product Insights
NewHereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2024
Empower your strategies with our Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2024 report and make more profitable business decisions. Hereditary inclusion body myopathy (h-IBM) is a rare, adult-onset muscle disorder. It is characterized by severe, progressive muscle weakness. Symptoms of IBM vary, but usually include progressive weakness in the muscles of the hand, forearm, thigh, and lower leg. Physical examination and medical history, blood tests to look for disease-specific enzymes or antibodies, nerve conduction studies to measure any...
-
Sector Analysis
NewData and Analytics Market Size, Trends, Drivers and Challenges, Vendor Landscape, Opportunities and Forecast to 2027
Data & Analytics Market Overview The global Data & Analytics market size was pegged at more than $100 billion in 2022. The market is expected to grow at a CAGR of more than 12% during the forecast period (2022-2027). The data & analytics market will be driven by increasing digitization across all spheres of life, creating data at an unprecedented level. Enterprises are increasingly becoming aware of the benefits of unlocking insights from the data that can provide to their...
-
Thematic Analysis
NewIT Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the cloud, data analytics, and future of work themes lead the thematic screen of GlobalData’s IT services sector scorecard. This is dominated by the global IT services giants Accenture, IBM, and Infosys, closely followed by Capgemini and Tata Consultancy Services (TCS). Indian heritage vendors occupy half of the top 10 vendor positions, suggesting they are successfully adapting their strategies to the long-term concern of a declining cost advantage versus their US and European peers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Polymyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide in Polymyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Polymyositis Drug Details: Froniglutide is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Froniglutide in Dermatomyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Dermatomyositis Drug Details: Froniglutide is under development for the treatment...
-
Thematic Analysis
NewApplication Software Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the artificial intelligence (AI), big data, and cloud computing-related themes lead the thematic screen of GlobalData’s application software sector scorecard. This screen is dominated by the large US cloud vendors (Microsoft, Amazon, and Alphabet), but also includes leading enterprise software companies such as IBM, SAP, and Infor, as well as Apple. There have been minor score changes for companies such as Broadcom, OpenText, and Software AG due to their divestitures following recent acquisitions.
-
Thematic Analysis
NewCloud Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
The thematic screen of GlobalData’s cloud services sector scorecard is led by the global hyperscalers Microsoft and Amazon, with Alphabet and IBM also in the top 10. Microsoft and Alphabet, in particular, are aggressively investing in generative artificial intelligence (AI), developing foundational large language models (LLM), and building the infrastructure to offer related services to customers. In recent months, Alphabet launched its Gemini AI model, Microsoft launched its own AI chips and also invested in Mistral, and Microsoft’s strategic partner...